Submitted by san2025 on January 12, 2022 - 9:33pm
| Title | Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm. |
| Publication Type | Journal Article |
| Year of Publication | 2015 |
| Authors | Chakraborty S, Rhee KY |
| Journal | Cold Spring Harb Perspect Med |
| Volume | 5 |
| Issue | 8 |
| Pagination | a021147 |
| Date Published | 2015 Apr 15 |
| ISSN | 2157-1422 |
| Keywords | Antitubercular Agents, Diarylquinolines, Drug Design, Drug Resistance, Bacterial, Drug Therapy, Combination, Ethambutol, Evolution, Chemical, Female, Humans, Isoniazid, Male, Mycobacterium tuberculosis, Pyrazinamide, Rifampin, Tuberculosis, Tuberculosis, Multidrug-Resistant |
| Abstract | Modern tuberculosis (TB) chemotherapy is widely viewed as a crowning triumph of anti-infectives research. However, only one new TB drug has entered clinical practice in the past 40 years while drug resistance threatens to further destabilize the pandemic. Here, we review a brief history of TB drug development, focusing on the evolution of mechanism(s)-of-action studies and key conceptual barriers to rational, mechanism-based drugs. |
| DOI | 10.1101/cshperspect.a021147 |
| Alternate Journal | Cold Spring Harb Perspect Med |
| PubMed ID | 25877396 |
| PubMed Central ID | PMC4526730 |